This effect could be mediated via the anti-PD1 treatment, that not only leads to an activation of cytotoxic T cells but to a downregulation of FOXP3 expression in the Treg population as well, as demonstrated in the study of Wang et al. using PBMCs from melanoma patients27. The gene discussed is FOXP3; the disease is melanoma.